Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The stock's rise snapped a four-day losing streak.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigine), an oral, non-opioid, highly selective ...
Vertex shares fell 15.4% after the company posted in-line Q4 results but disappointing Q1 2025 guidance. Adjusted earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results